Evidence map›Paper›PMID 35300879›Full record

ArticleUltrasound in medicine & biology2022

Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Rosalind P Candelaria, Beatriz E Adrada, Deanna L Lane, Gaiane M Rauch, Stacy L Moulder, Alastair M Thompson, Roland L Bassett, Elsa M Arribas, Huong T Le-Petross, Jessica W T Leung and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ultrasound in medicine & biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rosalind P CandelariaDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: rcandelaria@mdanderson.org.
Beatriz E AdradaDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Deanna L LaneDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gaiane M RauchDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stacy L MoulderDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alastair M ThompsonDepartment of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roland L BassettDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elsa M ArribasDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Huong T Le-PetrossDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jessica W T LeungDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David A SpakDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth E RavenbergDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jason B WhiteDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Vicente ValeroDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wei T YangDepartment of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

This study aimed to investigate mid-treatment breast tumor ultrasound characteristics that may predict eventual pathologic complete response (pCR) in triple-negative breast cancer; specifically, we examined associations between pCR and two parameters: tumor response pattern and tumor appearance. Ultrasound was performed at mid-treatment, defined as the completion of four cycles of anthracycline-based chemotherapy and before receiving taxane-based chemotherapy. Consensus imaging review was performed while blinded to pathology results (i.e., pCR/non-pCR) from surgery. Tumor response pattern was described as "complete," "concentric," "fragmented," "stable" or "progression." Tumor appearance was designated as "mass," "architectural distortion," "flat tumor bed" or "clip only." Univariate and multivariate regression analyses of 144 participants showed significant associations between mid-treatment response pattern and pCR (p = 0.0348 and p = 0.0173, respectively), with complete and concentric response patterns more likely to achieve pCR than other patterns. Univariate and multivariate regression analyses further showed significant associations between mid-treatment tumor appearance and pCR (p < 0.0001 for both), with persistent appearance of mass less likely than other appearances to achieve pCR. To conclude, our study demonstrated strong associations between pCR and both tumor response pattern and tumor appearance, thereby suggesting that these parameters have potential as qualitative imaging biomarkers of pCR in triple-negative breast cancer.

Indexed as

Triple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersChemotherapy, AdjuvantFemaleHumansNeoadjuvant TherapyBiomarkersNeoadjuvant therapyTreatment responseTriple-negative breast cancerUltrasound

Identifiers

PMID35300879
PMCPMC9050953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.